tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

REGN Stock Latest News

Regeneron’s Promising Study on REGN7999 for Iron Overload in Beta-Thalassemia
Company AnnouncementsRegeneron’s Promising Study on REGN7999 for Iron Overload in Beta-Thalassemia
7h ago
REGN
Regeneron’s REGN7544: A Promising Treatment for Sepsis-Induced Hypotension?
PremiumCompany Announcements
Regeneron’s REGN7544: A Promising Treatment for Sepsis-Induced Hypotension?
7h ago
REGN
Regeneron’s Linvoseltamab Study: A New Hope for Resistant Multiple Myeloma
PremiumCompany Announcements
Regeneron’s Linvoseltamab Study: A New Hope for Resistant Multiple Myeloma
7h ago
REGN
Regeneron’s Promising Phase 2 Study on Ovarian Cancer Treatment
PremiumCompany Announcements
Regeneron’s Promising Phase 2 Study on Ovarian Cancer Treatment
7h ago
REGN
Regeneron’s Innovative Approach: Pozelimab and Cemdisiran in PNH Treatment
PremiumCompany Announcements
Regeneron’s Innovative Approach: Pozelimab and Cemdisiran in PNH Treatment
7h ago
REGN
Regeneron’s Promising Factor XI Programs: A Potential Game-Changer in the Anticoagulation Market
PremiumRatingsRegeneron’s Promising Factor XI Programs: A Potential Game-Changer in the Anticoagulation Market
17h ago
REGN
Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer?
Premium
Company Announcements
Regeneron’s Promising Phase 3 Trial for Follicular Lymphoma: A Potential Game-Changer?
1d ago
REGN
Regeneron’s Cemiplimab Study: A Potential Game-Changer for Skin Cancer Treatment
Premium
Company Announcements
Regeneron’s Cemiplimab Study: A Potential Game-Changer for Skin Cancer Treatment
1d ago
REGN
Regeneron Advances in AMD Treatment: A Closer Look at the Ongoing Clinical Study
PremiumCompany Announcements
Regeneron Advances in AMD Treatment: A Closer Look at the Ongoing Clinical Study
1d ago
REGN
Regeneron price target raised to $781 from $753 at Bernstein
PremiumThe Fly
Regeneron price target raised to $781 from $753 at Bernstein
2d ago
REGN
Regeneron announces Phase 3 NIMBLE trial met primary, key secondary endpoints
PremiumThe Fly
Regeneron announces Phase 3 NIMBLE trial met primary, key secondary endpoints
3d ago
REGN
Regeneron’s Promising Phase 2 NSCLC Trial: A Potential Game-Changer?
PremiumCompany Announcements
Regeneron’s Promising Phase 2 NSCLC Trial: A Potential Game-Changer?
3d ago
REGN
Regeneron’s Innovative Gene Therapy Study for Hemophilia B: Market Implications and Progress
PremiumCompany AnnouncementsRegeneron’s Innovative Gene Therapy Study for Hemophilia B: Market Implications and Progress
4d ago
REGN
Regeneron’s Promising Phase 3 Trial for Lymphoma Treatment: What Investors Need to Know
Premium
Company Announcements
Regeneron’s Promising Phase 3 Trial for Lymphoma Treatment: What Investors Need to Know
4d ago
REGN
Regeneron’s Real-World Study on Aflibercept: Market Implications and Investor Insights
Premium
Company Announcements
Regeneron’s Real-World Study on Aflibercept: Market Implications and Investor Insights
4d ago
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Game Changer for Pediatric Prurigo Nodularis
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game Changer for Pediatric Prurigo Nodularis
4d ago
REGN
Regeneron’s PNH Study: A Promising Step in Rare Disease Treatment
PremiumCompany Announcements
Regeneron’s PNH Study: A Promising Step in Rare Disease Treatment
4d ago
REGN
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Prurigo Nodularis Treatment
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Prurigo Nodularis Treatment
6d ago
SNY
REGN
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?
PremiumCompany Announcements
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?
6d ago
NTLA
REGN
Regeneron’s Promising Pipeline: Buy Rating Backed by EYLEA HD Progress and Anticipated Approvals
PremiumRatingsRegeneron’s Promising Pipeline: Buy Rating Backed by EYLEA HD Progress and Anticipated Approvals
6d ago
REGN
Regeneron’s Promising Phase 3 Trial for Lymphoma Treatment: A Closer Look
Premium
Company Announcements
Regeneron’s Promising Phase 3 Trial for Lymphoma Treatment: A Closer Look
7d ago
REGN
Regeneron’s Real-World Study on Aflibercept: Key Insights for Investors
Premium
Company Announcements
Regeneron’s Real-World Study on Aflibercept: Key Insights for Investors
7d ago
REGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >